ELVN news

Latest 3 stories · newest Oct 14, 2026

ELVN

Enliven appoints Biopharma exec to Board ahead of Phase 3 relcobatinib trial

Enliven Therapeutics announced the appointment of Kristine Ball to its Board of Directors to help prepare for a pivotal Phase 3 trial of relcobatinib and future commercialization, reflecting a focus on its late-stage pipeline.

Leadership Oct 14, 2026 sentiment +0.50 SEC filing ↗

ELVN

Enliven reports 61% MMR in Phase 1b CML trial; FDA aligns on Phase 3 design

Enliven Therapeutics announced updated positive Phase 1 data for ELVN-001 in chronic myeloid leukemia with 61% overall response rates and FDA alignment on the 80 mg dose for the pivotal Phase 3 ENABLE-2 trial. The company expects to initiate the Phase 3 study in the second half of 2026, representing…

Regulatory Jun 11, 2026 sentiment +0.85 SEC filing ↗

ELVN

Stitch Fix, Intel, KLA And Other Big Stocks Moving Higher On Thursday

News Jun 11, 2026 sentiment 0.00 Source: benzinga.com ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same ELVN feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/ELVN/newsSTART FREE